Clinical Trial Update: ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Bayer reports completion of a Phase 2 clinical trial evaluating ZK 230211 in postmenopausal women with metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ZK 230211

Snippet

Sponsor: Bayer | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED